quinazolines has been researched along with Cardiovascular Diseases in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.76) | 18.7374 |
| 1990's | 4 (9.52) | 18.2507 |
| 2000's | 7 (16.67) | 29.6817 |
| 2010's | 28 (66.67) | 24.3611 |
| 2020's | 1 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Li, WQ; Li, YJ; Ma, WJ; Yin, YC; Zhang, BK | 1 |
| Calosing, C; Gilham, D; Halliday, C; Jahagirdar, R; Johansson, J; Kulikowski, E; Sweeney, M; Tsujikawa, LM; Wasiak, S; Wong, NC | 1 |
| Aglietta, M; Bonzano, A; Cagnazzo, C; Depetris, I; Filippi, R; Leone, F; Marino, D | 1 |
| Dziadziuszko, R; Palczewski, P; Płatek, AE; Szymański, FM; Łęgosz, P | 1 |
| Braconi, C; Chau, I; Cunningham, D; Forster, M; Gerlinger, M; Kalaitzaki, E; Khan, K; Rane, JK; Rao, S; Starling, N; Valeri, N; Watkins, D | 1 |
| Li, JJ; Tian, KM; Xu, SW | 1 |
| Emser, A; Gong, Y; von Eynatten, M; Woerle, HJ | 1 |
| Grunberger, G | 1 |
| Capdevila, J; Filetti, S; Grande, E; Kreissl, MC; Newbold, K; Reinisch, W; Robert, C; Schlumberger, M; Tolstrup, LK; Zamorano, JL | 1 |
| Gu, JA; Huang, SH; Huang, ST; Lee, CM; Lin, CM; Lin, FY; Rau, TG; Yang, CH; Yang, WC | 1 |
| Anastassiadis, E; Diessel, S; Forst, T; Löffler, A; Pfützner, A | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Hasegawa, Y; Katayama, T; Kim-Mitsuyama, S; Koibuchi, N; Kusaka, H; Lin, B; Ma, M; Nakagawa, T; Sueta, D; Toyama, K; Uekawa, K | 1 |
| Chinetti-Gbaguidi, G; Colin, S; Kuivenhoven, JA; Staels, B | 1 |
| Birtolo, C; Codeluppi, K; Cortelazzo, S; Fama, A; Gastl, G; Gugliotta, G; Gugliotta, L; Marcheselli, L; Piccin, A; Santoro, U; Steurer, M; Tieghi, A; Tortorella, G | 1 |
| Davis, J; Gadkar, K; Lu, J; Mazer, NA; Ramanujan, S; Sahasranaman, S | 1 |
| Gilham, D; Gordon, A; Halliday, C; Johansson, J; Kulikowski, E; McLure, K; Norek, K; Patel, RG; Sweeney, M; Tsujikawa, LM; Wasiak, S; Wong, NC; Young, P | 1 |
| Chen, L; Fang, Q; Li, W; Li, X; Liang, G; Wang, J; Wang, L; Wang, Y; Zhang, Y; Zhong, P | 1 |
| Birgegård, G | 1 |
| Castaldo, V; Ferrara, ML; Gridelli, C; Maione, P; Mazzeo, N; Palazzolo, G; Rossi, A | 1 |
| McNeill, E | 1 |
| Vannucchi, AM | 1 |
| Awada, A; Azim, HA; Metzger Filho, O; Saini, KS | 1 |
| Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A | 1 |
| Cacciola, E; Cacciola, R; Candoni, A; Ciancia, R; Codeluppi, K; Crugnola, M; Grossi, A; Gugliotta, L; Iurlo, A; Liberati, AM; Lunghi, M; Martinelli, V; Mazzucconi, MG; Palmieri, F; Pierri, I; Scalzulli, PR; Specchia, G; Tieghi, A; Tortorella, G; Usala, E; Vannucchi, AM; Vianelli, N | 1 |
| Besses, C; Martínez-Sellés, M | 1 |
| Johansen, OE; Neubacher, D; Patel, S; von Eynatten, M; Woerle, HJ | 1 |
| Joy, TR | 1 |
| Abbineni, C; Balaji, G; Balasubrahmanyam, D; Cheera, S; Elster, L; Frimurer, TM; Harinder Reddy, K; Högberg, T; Jadhav, VP; Kanna Reddy, HR; Khanna, I; Rist, Ø; Sasmal, PK; Sasmal, S; Sebastian, VJ; Shashikumar, D; Sihorkar, V; Singh, MP; Srinivas, G; Suresh, J; Talwar, R | 1 |
| Imaizumi, S; Miura, S; Saku, K; Uehara, Y; Yahiro, E | 1 |
| Goto, K | 1 |
| Frantz, S | 1 |
| Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, J | 1 |
| O'Leary, MP | 1 |
| Brogden, RN; Kellerman, D; Romankiewicz, JA; Stanaszek, WF | 1 |
| Kather, H | 1 |
| Buzelin, JM; Delauche-Cavallier, MC; Geffriaud-Ricouard, C; Roth, S; Santoni, JP | 1 |
| Hara, Y; Harano, Y; Kanazawa, A; Nishioheda, Y; Ryomoto, K; Shinozaki, K; Suzuki, M; Tsushima, M | 1 |
| Mesa, RA; Petitt, RM; Silverstein, MN; Solberg, LA; Tefferi, A | 1 |
| Green, AR | 1 |
| De la Rosette, JJ; Farmer, RD; Herings, RM; Leufkens, HG; Man in 't Veld, AJ; Souverein, PC | 1 |
| Ijzerman, AP; Timmerman, H; van Muijlwijk-Koezen, JE | 1 |
23 review(s) available for quinazolines and Cardiovascular Diseases
| Article | Year |
|---|---|
Calcitonin gene‑related peptide‑mediated pharmacological effects in cardiovascular and gastrointestinal diseases (Review).
Topics: Calcitonin Gene-Related Peptide; Cardiovascular Diseases; Gastrointestinal Diseases; Gene Expression Regulation; Humans; Indole Alkaloids; Molecular Targeted Therapy; Nitroglycerin; Quinazolines; Up-Regulation | 2021 |
Fluoropyrimidine-induced cardiotoxicity.
Topics: Acetates; Capecitabine; Cardiotoxicity; Cardiovascular Diseases; Drug Combinations; Fluorouracil; Humans; Neoplasms; Pyrimidines; Pyrrolidines; Quinazolines; Thiophenes; Thymine; Trifluridine; Uracil; Uridine | 2018 |
Rutaecarpine: A promising cardiovascular protective alkaloid from Evodia rutaecarpa (Wu Zhu Yu).
Topics: Alkaloids; Animals; Anti-Inflammatory Agents; Antioxidants; Cardiotonic Agents; Cardiovascular Diseases; Evodia; Humans; Hypolipidemic Agents; Indole Alkaloids; Platelet Aggregation Inhibitors; Quinazolines; Vasodilator Agents | 2019 |
Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials.
Topics: Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Kidney Diseases; Linagliptin; Purines; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2013 |
Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines | 2013 |
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.
Topics: Carcinoma, Neuroendocrine; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Diseases; Humans; Male; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Piperidines; Prognosis; Quinazolines; Risk Assessment; Thyroid Neoplasms; Treatment Outcome | 2013 |
Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Cardiovascular Diseases; Humans; Imidazoles; Incidence; Indazoles; Indoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk; Sunitinib | 2014 |
Emerging small molecule drugs.
Topics: Animals; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Drug Design; Dyslipidemias; Humans; Hypolipidemic Agents; Liver X Receptors; Molecular Targeted Therapy; Orphan Nuclear Receptors; Peroxisome Proliferator-Activated Receptors; Quinazolines; Quinazolinones; Signal Transduction | 2015 |
The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.
Topics: Age Factors; Bone Marrow; Cardiovascular Diseases; Humans; Interferon-alpha; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Tachycardia; Thrombocythemia, Essential | 2016 |
Treatment of advanced non-small-cell lung cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cardiovascular Diseases; Cisplatin; Clinical Trials as Topic; Comorbidity; Contraindications; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Vascular Endothelial Growth Factor A | 2009 |
RVX-208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases.
Topics: Animals; Apolipoprotein A-I; Cardiovascular Diseases; Clinical Trials as Topic; Gene Expression; Humans; Quinazolines; Quinazolinones | 2010 |
JAK2 mutation and thrombosis in the myeloproliferative neoplasms.
Topics: Amino Acid Substitution; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Incidence; Interferon-alpha; Janus Kinase 2; Multicenter Studies as Topic; Mutation, Missense; Myeloproliferative Disorders; Phenotype; Point Mutation; Quinazolines; Thrombophilia; Thrombosis | 2010 |
Prevention and management of major side effects of targeted agents in breast cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast; Breast Neoplasms; Cardiovascular Diseases; Female; Gastrointestinal Diseases; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Skin Diseases; Trastuzumab | 2012 |
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Breast Neoplasms; Cardiotoxins; Cardiovascular Diseases; Female; Heart Failure; Humans; Indoles; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk Assessment; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.
Topics: Aged; Angina, Unstable; Biomarkers; Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Female; Glycated Hemoglobin; Hospitalization; Humans; Linagliptin; Male; Middle Aged; Myocardial Infarction; Patient Safety; Proportional Hazards Models; Prospective Studies; Purines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2012 |
Novel HDL-based therapeutic agents.
Topics: Animals; Apolipoprotein A-I; Biomarkers; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Humans; Hypolipidemic Agents; Molecular Mimicry; Quinazolines; Quinazolinones; Treatment Outcome | 2012 |
Chymase inhibitors.
Topics: Acetamides; Animals; Atrial Fibrillation; Azetidines; Benzoates; Cardiovascular Diseases; Chymases; Heart Failure; Humans; Hypertension; Mast Cells; Oxazoles; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
[Prospects for endothelin-related drugs].
Topics: Animals; Aspartic Acid Endopeptidases; Bosentan; Cardiovascular Diseases; Drug Design; Endothelin Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Hemodynamics; Humans; Metalloendopeptidases; Organophosphonates; Peptides, Cyclic; Quinazolines; Receptors, Endothelin; Sulfonamides; Sulfonylurea Compounds; Tetracyclines; Tetrazoles | 2004 |
Treatment and pharmacologic management of BPH in the context of common comorbidities.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Comorbidity; Doxazosin; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Global Health; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Transurethral Resection of Prostate; Treatment Outcome | 2006 |
Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Heart Failure; Heart Rate; Hemodynamics; Humans; Hypertension; Kidney; Lipid Metabolism; Prazosin; Quinazolines; Regional Blood Flow; Renin-Angiotensin System | 1983 |
Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.
Topics: Animals; Bone Marrow; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Hematopoiesis; Hemodynamics; Humans; Megakaryocytes; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombosis | 1997 |
The pathogenesis and management of essential thrombocythaemia.
Topics: Acute Disease; Alkylating Agents; Aspirin; Cardiovascular Diseases; Clone Cells; Gene Expression; Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid; Megakaryocytes; Platelet Aggregation Inhibitors; Quinazolines; Risk; Thrombocythemia, Essential; Thrombophilia | 1999 |
The adenosine A3 receptor and its ligands.
Topics: Adenosine; Amino Acid Sequence; Animals; Cardiovascular Diseases; Cloning, Molecular; Flavonoids; Humans; Immune System Diseases; Lung Diseases; Models, Animal; Molecular Sequence Data; Protein Binding; Pyrans; Pyridines; Quinazolines; Receptors, Purinergic; Sequence Alignment; Species Specificity; Triazoles; Xanthines | 2001 |
4 trial(s) available for quinazolines and Cardiovascular Diseases
| Article | Year |
|---|---|
Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Linagliptin; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Postprandial Period; Proinsulin; Purines; Quinazolines; Risk Factors; Sulfonylurea Compounds | 2014 |
Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study.
Topics: Adult; Aged; Cardiovascular Diseases; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Monitoring, Physiologic; Natriuretic Peptide, Brain; Peptide Fragments; Platelet Aggregation Inhibitors; Prospective Studies; Quinazolines; Thrombocythemia, Essential; Troponin I | 2015 |
Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Heart Failure; Heart Rate; Hemodynamics; Humans; Hypertension; Kidney; Lipid Metabolism; Prazosin; Quinazolines; Regional Blood Flow; Renin-Angiotensin System | 1983 |
Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Delayed-Action Preparations; Double-Blind Method; Humans; Hypertension; Male; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urinary Retention; Urination | 1997 |
16 other study(ies) available for quinazolines and Cardiovascular Diseases
| Article | Year |
|---|---|
Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208).
Topics: Animals; Cardiovascular Diseases; Cells, Cultured; Complement Activation; Complement Inactivating Agents; Complement System Proteins; Cytokines; Gene Expression Profiling; Hepatocytes; Humans; Immunity, Innate; Mice, SCID; Primary Cell Culture; Proteins; Proteomics; Quinazolines; Quinazolinones; Signal Transduction | 2017 |
Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cardiotonic Agents; Cardiovascular Diseases; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Nebivolol; Piperazines; Protein Kinase Inhibitors; Quinazolines; Ramipril | 2018 |
Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiotoxicity; Cardiovascular Diseases; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Prognosis; Quinazolines; Retrospective Studies; Safety; Survival Rate; Thiophenes | 2019 |
Low-cytotoxic synthetic bromorutaecarpine exhibits anti-inflammation and activation of transient receptor potential vanilloid type 1 activities.
Topics: Anti-Inflammatory Agents; Cardiovascular Diseases; Drugs, Chinese Herbal; Evodia; Gene Expression Regulation; Humans; Indole Alkaloids; Inflammation; Macrophages; Nitric Oxide Synthase Type II; Quinazolines; TRPV Cation Channels | 2013 |
DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure.
Topics: Animals; Blood Glucose; Blood Pressure; Blood Pressure Determination; Cardiovascular Diseases; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Heart; Hypertension; Linagliptin; Male; Purines; Quinazolines; Rats; Rats, Inbred Dahl; Sodium Chloride, Dietary | 2014 |
Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach.
Topics: Apolipoprotein A-I; Biological Transport; Biomarkers; Cardiovascular Diseases; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Models, Biological; Quinazolines; Quinazolinones; Risk Factors; Up-Regulation | 2016 |
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease.
Topics: Apolipoprotein A-I; Atherosclerosis; Cardiovascular Diseases; Cells, Cultured; Cholesterol, HDL; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Gene Expression Profiling; Hepatocytes; Humans; Hypolipidemic Agents; Liver; Male; Oligonucleotide Array Sequence Analysis; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic; Retrospective Studies; Signal Transduction; Time Factors; Up-Regulation | 2016 |
EGFR Inhibition Blocks Palmitic Acid-induced inflammation in cardiomyocytes and Prevents Hyperlipidemia-induced Cardiac Injury in Mice.
Topics: Animals; Apolipoproteins E; Apoptosis; Cardiovascular Diseases; Cell Line; Diet, High-Fat; ErbB Receptors; Hyperlipidemias; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Palmitic Acid; Protein Kinase Inhibitors; Quinazolines; Rats; src-Family Kinases; Toll-Like Receptor 4; Tyrphostins | 2016 |
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Child; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Thrombocythemia, Essential; Withholding Treatment; Young Adult | 2011 |
Anagrelide and cardiovascular events. Much ado about nothing?
Topics: Cardiovascular Diseases; Female; Humans; Male; Quinazolines; Thrombocythemia, Essential; Withholding Treatment | 2011 |
Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists: part 2.
Topics: Cardiovascular Diseases; Drug Design; Humans; Quinazolines; Receptors, Pituitary Hormone; Receptors, Somatostatin; Structure-Activity Relationship | 2012 |
Drug discovery: playing dirty.
Topics: Animals; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Clozapine; Depression; Drug Approval; Drug Design; Drug Evaluation, Preclinical; Drug Industry; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Sensitivity and Specificity; Substrate Specificity; Therapeutics; United States; United States Food and Drug Administration | 2005 |
Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Drug Administration Schedule; Humans; Hypertension; Male; Middle Aged; Myocardial Ischemia; Quinazolines; Urination Disorders | 2006 |
[Hypertensive therapy with prazosin. Concomitant cardiovascular, metabolic and respiratory diseases. Proven facts and potential aspects].
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Cardiovascular Diseases; Diabetes Complications; Humans; Hypertension; Kidney; Lipids; Myocardial Infarction; Prazosin; Quinazolines; Respiratory Tract Diseases | 1984 |
Clinical impact of insulin resistance syndrome in cardiovascular diseases and its therapeutic approach.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Cilazapril; Humans; Insulin Resistance; Middle Aged; Quinazolines | 1996 |
Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adult; Aged; Bias; Cardiovascular Diseases; Case-Control Studies; Finasteride; Humans; Male; Middle Aged; Morbidity; Netherlands; Prazosin; Prognosis; Prostatic Hyperplasia; Quinazolines; Research Design; Risk Factors; Sulfonamides; Tamsulosin | 2001 |